Authors: Filip Šustr; Miroslav Souček Authors‘ workplace: II. interní klinika, Fakultní nemocnice u svaté Anny v Brně, Brno Published in: Vnitř Lék 2020; 66(3): 197-198 Category: Information
Cardiovascular diseases (CVD) are still at the first place in the case of mortality in European countries. Consistent secondary prevention for CVD is very important aspect in the fight with this negative statistics. We consider antithrombotic treatment as a gold standard in secondary prevention for CVD . There are a lot of latest trials about this problematics. COMPASS trial targets the effectiveness of rivaroxaban in patients with CVD as a secondary prevention. The results of this trial are very positive about using rivaroxaban and acetylsalicylic acid together in effort to avoid progression or relapse of CVD.
COMPASS – rivaroxaban – ASA – coronary artery disease
1. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of corona ‑ ry patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636–648. doi: 10.1177/2047487315569401
2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477. doi: 10.1093/ eurheartj/ehz425
3. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012; 366(1): 9–19. doi: 10.1056/NEJMoa1112277
4. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319–1330. doi: 10.1056/NEJMoa1709118
5. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double‑blind, placebo‑controlled trial. The Lancet. 2018; 391(10117): 205–218. doi: 10.1016/S0140-6736(17)32458-3
6. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double‑blind, placebo‑controlled trial. The Lancet. 2018; 391(10117): 219–229. doi: 10.1016/S0140-6736(17)32409-1
7. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‑surgical patients: Definitions of major bleeding in clinical studies. J Thromb Haemost. 2005;3(4):692-694. doi: 10.1111/j.1538-7836.2005.01204.x
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
